Company Description
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.
The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform.
Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| Country | United States |
| Founded | 2003 |
| IPO Date | Apr 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 286 |
| CEO | Kenneth Galbraith |
Contact Details
Address: 108 Patriot Drive, Suite A Middletown, Delaware 19709 United States | |
| Phone | 302 274 8744 |
| Website | zymeworks.com |
Stock Details
| Ticker Symbol | ZYME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403752 |
| CUSIP Number | 98985W102 |
| ISIN Number | US98985Y1082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kenneth H. Galbraith C.A. | Chairman of the Board, Chief Executive Officer and President |
| Dr. Paul A. Moore Ph.D. | Chief Scientific Officer |
| Mark Hollywood | Executive Vice President and Head of Technical and Manufacturing Operations |
| Shrinal Inamdar | Director of Investor Relations |
| Daniel Dex J.D., Ph.D. | Senior Vice President, Corporate Secretary and General Counsel |
| Diana Papove | Senior Manager of Corporate Communications |
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development |
| Laura O'Connor | Vice President of Human Resources and DEI |
| Dr. Jeffrey Smith M.D. | Executive Vice President and Chief Medical Officer |
| John Fann Ph.D. | Senior Vice President of Process Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2022 | 15-12G | Securities registration termination |
| Oct 21, 2022 | 8-K | Current Report |
| Oct 19, 2022 | 8-K | Current Report |
| Oct 18, 2022 | 8-K | Current Report |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |